Soligenix, Inc. announced on March 6, 2025, that its lead investigators presented findings from recent supportive trials for HyBryte™ in cutaneous T-cell lymphoma (CTCL) and SGX302 in mild-to-moderate psoriasis. These presentations took place at the United States Cutaneous Lymphoma Consortium (USCLC) Workshop and the American Academy of Dermatology (AAD) Annual Meeting.
Dr. Ellen Kim presented results from an ongoing investigator-initiated study using HyBryte™ as a long-term CTCL treatment, while Dr. Neal Bhatia discussed general considerations on topical and photodynamic therapy, including synthetic hypericin, for psoriasis. The data highlighted the utility of longer treatment times and HyBryte's favorable safety profile.
These presentations further elaborated on findings demonstrating the lack of significant systemic exposure to hypericin after topical application and its relative efficacy and tolerability compared to Valchlor®. Such dissemination of data is crucial for informing the medical community about the potential of Soligenix's therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.